Trial Profile
A 2-part, Cross-over Trial of NOMAC-E2 to Assess Bioequivalence Between the Phase 3 Pivotal Clinical Batches and a Batch Prepared Using the Commercial Drug Manufacturing Process
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Estradiol/nomegestrol (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme; Organon; Schering-Plough
- 06 May 2011 New trial record